Clinical Trials Browser

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

450 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06467357 2026-02-17

DESTINY-BTC01

Phase 3 Recruiting

620 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT05945732 2026-02-12

DESTINY Breast Respond HER2-low Europe

Recruiting

1,155 enrolled

Breast

Breast Neoplasms

NCT07015697 2026-02-10

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Phase 1 Recruiting

76 enrolled

Recurrence

NCT05950945 2026-02-09

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Phase 3 Recruiting

250 enrolled

Breast

Breast Neoplasms

NCT07022483 2026-02-04

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Phase 3 Recruiting

710 enrolled

Gynecologic

Neoplasms, Endometrial Neoplasms

NCT04482309 2026-01-21

DPT02

Phase 2 Recruiting

468 enrolled 1 FDA

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT06210776 2026-01-12

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Recruiting

800 enrolled

Breast

Breast Neoplasms

NCT06899126 2026-01-08

DESTINY-Lung06

Phase 3 Recruiting

686 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06429761 2025-11-24

STRIDE

Phase 4 Recruiting

100 enrolled

Breast

Breast Neoplasms

NCT04686305 2025-11-13

DL03

Phase 1 Recruiting

244 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06271837 2025-10-22

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Phase 2 Recruiting

175 enrolled

Breast

Breast Neoplasms

NCT06846996 2025-07-08

RECOVER

Recruiting

260 enrolled

Gastrointestinal

HER2-positive Gastric Cancer

NCT06727227 2025-07-01

EXPLORE

Recruiting

135 enrolled

Breast

Breast Neoplasms

NCT06832202 2025-06-15

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

Phase 2 Recruiting

50 enrolled

Breast

HER2-low Hormone Receptor Positive Breast Cancer

NCT06220864 2025-03-13

SNV1521 in Participants with Advanced Solid Tumors

Phase 1 Recruiting

200 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Phase 1/2 Recruiting

358 enrolled

DermatologicGastrointestinalGenitourinarySarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT06525298 2024-09-19

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Phase 1/2 Recruiting

144 enrolled

Other solid neoplasm

Advanced Solid Tumor